<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AGGRASTATÂ - tirofiban hydrochlorideÂ injection, solutionÂ </strong><br>Medicure International Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AGGRASTATÂ® (tirofiban hydrochloride) safely and effectively. See full prescribing information for AGGRASTAT<br>AGGRASTATÂ® (tirofiban hydrochloride) injection, for intravenous use<br><span class="Bold">Initial U.S. Approval: 1998</span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration (<a href="#L2b94c6f0-f83f-47ad-861e-5af991ab215b">2</a>)Â Â Â Â  4/2015 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">
                 AGGRASTATÂ® is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>/repeat cardiac procedure) in patients with non-ST elevation <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> (NSTE-ACS). 
                  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance â‰¤60 mL/min, give 25 mcg/kg within 5 minutes and then 0.075 mcg/kg/min. (<a href="#L2b94c6f0-f83f-47ad-861e-5af991ab215b">2</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Intravenous injection premixed: 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) with sodium chloride.  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of AGGRASTAT. (<a href="#Lb0d839f3-a70e-435a-a7b5-132618b1fbef">4</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with prior exposure to AGGRASTAT. (<a href="#Lb0d839f3-a70e-435a-a7b5-132618b1fbef">4</a>)</li>
<li>Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, major surgical procedure or severe physical <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> within the previous month. (<a href="#Lb0d839f3-a70e-435a-a7b5-132618b1fbef">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>AGGRASTAT can cause serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> cannot be controlled discontinue AGGRASTAT. (<a href="#L208a409c-101a-42fe-bbb1-94c994298c81">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Discontinue AGGRASTAT and heparin.  (<a href="#L208a409c-101a-42fe-bbb1-94c994298c81">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> is the most commonly reported adverse reaction. (<a href="#Ldd5c4a27-47e7-45df-ab32-cd3a5398427b">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Medicure at 1-800-509-0544 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>. </span> </p>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Coadministration of antiplatelet agents, thrombolytics, heparin, or aspirin increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#Lda8c1d64-ccc1-4382-b922-127f2d68c6a8">7</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>: Reduce the dose in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. (<a href="#La0968bfe-5e14-4e66-9c27-dd63012239b0">8.6</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
					</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS 
					</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> 
							</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS 
					</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience 
							</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS 
					</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS 
					</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
							</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
							</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use
							</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use
							</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>
							</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE 
					</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION 
					</a></h1>
<h1><a href="#section-11" class="toc">12   CLINICAL PHARMACOLOGY
					</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
							</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
							</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
							</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
					</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 	</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
					</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
					</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">
             AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>/repeat cardiac procedure) in patients with non-ST elevation <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> (NSTE-ACS).
            </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="L2b94c6f0-f83f-47ad-861e-5af991ab215b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
					</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min (or 0.075 mcg/kg/min for patients with creatinine clearance â‰¤60 mL/min), for up to 18 hours. This is not the regimen that was used in studies that established effectiveness of AGGRASTAT <span class="Italics">[see Clinical Studies (14)]</span>. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">The instructions by weight and creatinine clearance (CrCl) are tabulated in Table 1.</span></p>
<a name="col1"></a><table frame="box" width="50%">
<caption><span>Table 1 Dosing by Weight and CrCl</span></caption>
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First" style="border-left:1px solid;"><span class="Bold"><span class="XmChange">Weight</span></span><br><span class="Bold">(kg)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First"><span class="Bold">Within 5 min
<br>All Patients<br> (mL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Maintenance Infusion Rate<br>(mL/hr.)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">CrCl &gt;60 mL/min</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">CrCl â‰¤60 mL/min</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange">30-37</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange">38-45</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.75</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange">46-54</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>55-62</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>63-70</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>71-79</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.75</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>80-87</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>88-95</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>96-104</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>105-112</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.75</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>113-120</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">58</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>121-128</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11.25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>129-137</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">66.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>138-145</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.75</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First" style="border-left:1px solid;"><span class="XmChange"></span>146-153</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">75</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.5</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Important Administration Instructions</span></span></p>
<ol>
<li>To open the container, first tear off its foil overpouch. The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually. Check for leaks by squeezing the inner bag firmly; if any leaks are found or <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> is suspect then the solution should be discarded. Do not use unless the solution is clear and the seal is intact. Suspend the container from its eyelet support, remove the plastic protector from the outlet port, and attach a conventional administration set. </li>
<li>You may administer AGGRASTAT in the same intravenous line as atropine sulfate, dobutamine, dopamine, epinephrine hydrochloride (HCl), famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl. Do not administer AGGRASTAT through the same IV line as diazepam. </li>
<li>Do not add other drugs or remove solution directly from the bag with a syringe.</li>
<li>Do not use plastic containers in series connections; such use can result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> by drawing air from the first container if it is empty of solution.</li>
<li>Discard any unused portion left in the bag. </li>
</ol>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Lb21be3a1-3e0d-4a2b-ba3c-d6dd2e8f5d04"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">FOR INTRAVENOUS USE ONLY</p>
<p>AGGRASTAT Injection Premixed 5 mg tirofiban per 100 mL (50 mcg per mL) and 12.5 mg tirofiban per 250 mL (50 mcg per mL) are clear, non-preserved, sterile solutions premixed in a vehicle made iso-osmotic with sodium chloride.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Lb0d839f3-a70e-435a-a7b5-132618b1fbef"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">AGGRASTAT is contraindicated in patients with:</p>
<ul>
<li>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to AGGRASTAT (i.e., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>) <span class="Italics">[see Adverse Reactions (6.2)]</span>.</li>
<li>A history of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> following prior exposure to AGGRASTAT <span class="Italics">[see Adverse Reactions (6.1)]</span>.</li>
<li>Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or a history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, major surgical procedure or severe physical <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> within the previous month <span class="Italics">[see Adverse Reactions (6.1)]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="L208a409c-101a-42fe-bbb1-94c994298c81"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS 
					</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="L80ffb0cf-8664-4c31-982f-f6c40aa1f4d9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> 
							</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> is the most common complication encountered during therapy with AGGRASTAT.  Most <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc.  </p>
<p>Concomitant use of fibrinolytics, oral anticoagulants and antiplatelet drugs increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L89f1d6bf-da42-4687-816f-6f6ee7bb96d9"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First">Profound <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has been reported with AGGRASTAT.  Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to &lt;90,000/mm<span class="Sup">3</span>, monitor platelet counts to exclude pseudothrombocytopenia. If <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> is confirmed, discontinue AGGRASTAT and heparin. Previous exposure to a glycoprotein (GP) IIb/IIIa receptor antagonist may increase the risk of developing <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><span class="Italics"> [see Adverse Reactions (6.1)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Ldd5c4a27-47e7-45df-ab32-cd3a5398427b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS 
					</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb5bcbd2d-a896-47cf-867e-afc558771844"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In the PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management), PRISM-PLUS (Platelet Receptor Inhibition for Ischemic Syndrome Management â€” Patients Limited by Unstable Signs and Symptoms) and RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) trials, 1946 patients received AGGRASTAT in combination with heparin and 2002 patients received AGGRASTAT alone for about 3 days. Forty-three percent of the population was &gt;65 years of age and approximately 30% of patients were female. In clinical studies with the recommended regimen (25 mcg/kg bolus followed by a 0.15 mcg/kg/min maintenance infusion), AGGRASTAT was administered in combination with aspirin, clopidogrel and heparin or bivalirudin to over 8000 patients for typically â‰¤24 hours. Approximately 30% of the population was &gt;65 years of age and approximately 25% were female.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="L9a1fd6dc-67c2-4dde-9cd8-9921d359972b"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></h3>
<p class="First"><span class="Italics"><span class="Underline">PRISM-PLUS Regimen</span></span></p>
<p>The incidences of major and minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> using the TIMI criteria in the PRISM-PLUS study are shown below.
</p>
<a name="col3"></a><table frame="box" width="50%">
<caption><span>Table 2 TIMI Major and Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in PRISM-PLUS</span></caption>
<colgroup>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
</colgroup>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Major = Hemoglobin drop of &gt;5.0 g/L with or without an identified site, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, or <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Minor = Hemoglobin drop of &gt;3.0 g/L with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from a known site, spontaneous gross <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span> or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.  </dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>0.4 mcg/kg/min initial infusion; 0.10 mcg/kg/min maintenance infusion.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First">PRISM-PLUS
                            </p>
<p>(NSTE-ACS)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></p>
<p>(TIMI Criteria)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">AGGRASTAT<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>+ Heparin
                            </p>
<p>(n=773)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Heparin alone
                            </p>
<p>(n=797)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> 
                            </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>
                            </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.0%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><p class="First">Transfusions</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.0%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8%</p></td>
</tr>
</tbody>
</table>
<p>The incidence rates of TIMI major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients undergoing percutaneous procedures in PRISM-PLUS are shown below.</p>
<a name="col4"></a><table frame="box" width="70%">
<caption><span>Table 3 TIMI Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Associated with Percutaneous Procedures in PRISM-PLUS</span></caption>
<colgroup>
<col align="left" width="40%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<p class="First">AGGRASTAT +</p>
<p>Heparin</p>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">Heparin alone</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Prior to Procedures</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">773</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">797</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Following Angiography</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">697</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">708</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><p class="First">Following PTCA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">239</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">236</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.2</p></td>
</tr>
</tbody>
</table>
<p>The incidence rates of TIMI major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients undergoing coronary artery bypass graft surgery (CABG) in PRISM-PLUS within one day of discontinuation of AGGRASTAT were 17% on AGGRASTAT plus heparin (N=29) and 35% on heparin alone (N=31).  </p>
<p><span class="Italics"><span class="Underline">Recommended (â€œHigh-Dose Bolusâ€?) Regimen</span></span></p>
<p>Rates of major bleeds (including any intracranial, intraocular or <span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">retroperitoneal hemorrhage</span>, clinically overt signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> associated with a drop in hemoglobin of &gt;3 g/dL or any drop in hemoglobin by 4g/dL, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring transfusion of &gt;2U blood products, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> directly resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within 7 days or hemodynamic compromise requiring intervention) were consistent with the rates observed in subjects administered the PRISM-PLUS regimen of AGGRASTAT. There was a trend toward greater <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">ST segment elevation myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) patients treated with fibrinolytics prior to administration of AGGRASTAT using the recommended regimen during rescue PCI. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lcd1eff6f-25fe-42f6-b947-8eb58c023c93"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </span></h3>
<p class="First">The incidences of non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse events that occurred at an incidence of &gt;1% and numerically higher than control, regardless of drug relationship, are shown below:</p>
<a name="col7"></a><table frame="box" width="50%">
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">AGGRASTAT + Heparin</p>
<p>(N=1953)</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Heparin alone</p>
<p>(N=1887)</p>
<p>%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Italics">Body as a Whole</span></p>
<p>Â Â Â Â <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, pelvic</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â Â Reaction, vasovagal</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Italics">Cardiovascular System</span></p>
<p>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â Â Dissection, coronary artery</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Italics">Musculoskeletal System</span></p>
<p>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, leg</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Italics">Nervous System/Psychiatric</span></p>
<p>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Italics">Skin and Skin Appendage</span></p>
<p>Â Â Â Â <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="Lcf5d4887-5aeb-4b3a-a264-5c35c5702add"></a><a name="section-6.1.2.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></h4>
<p class="First">Patients treated with AGGRASTAT plus heparin, were more likely to experience decreases in platelet counts than were those on heparin alone. These decreases were reversible upon discontinuation of AGGRASTAT. The percentage of patients with a decrease of platelets to &lt;90,000/mm<span class="Sup">3</span> was 1.5%, compared with 0.6% in the patients who received heparin alone. The percentage of patients with a decrease of platelets to &lt;50,000/mm<span class="Sup">3</span> was 0.3%, compared with 0.1% of the patients who received heparin alone. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lce5593f4-5a61-4de3-9e92-3992a3bca222"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience 
							</h2>
<p class="First">The following additional adverse reactions have been identified during post-approval use of AGGRASTAT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.  </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have occurred during the first day of AGGRASTAT infusion, during initial treatment, and during readministration of AGGRASTAT. Some cases have been associated with severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet counts &lt;10,000/mm<span class="Sup">3</span>). No information is available on the formation of antibodies to tirofiban. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Lda8c1d64-ccc1-4382-b922-127f2d68c6a8"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS 
					</h1>
<p class="First"><span class="Bold">Use of thrombolytics, anticoagulants, and other antiplatelet agents</span>. 
            </p>
<p>Coadministration of antiplatelet agents, thrombolytics, heparin, and aspirin increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. 

</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="La0968bfe-5e14-4e66-9c27-dd63012239b0"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS 
					</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="L56048ca6-c97d-491d-a29e-80ccbb5fde74"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
							</h2>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Tirofiban has been shown to cross the placenta in pregnant rats and rabbits. Studies with tirofiban HCl at intravenous doses up to 5 mg/kg/day (about 5 and 13 times the maximum recommended daily human dose for rat and rabbit, respectively, when compared on a body surface area basis) have revealed no harm to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="L7a68eae9-ba60-4816-b2d6-5f3dfb7036b9"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
							</h2>
<p class="First">It is not known whether tirofiban is excreted in human milk. However, significant levels of tirofiban were shown to be present in rat milk. Because many drugs are excreted in human milk, and because of the potential for adverse effects on the nursing infant, discontinue nursing or discontinue AGGRASTAT.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Ld7d80a64-75e8-41a2-9c87-ef8d411ee1b1"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use
							</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Lf5913d1c-b399-4fbb-bca6-ee640af34c07"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use
							</h2>
<p class="First">Of the total number of patients in controlled clinical studies of AGGRASTAT, 43% were 65 years and over, while 12% were 75 and over. With respect to efficacy, the effect of AGGRASTAT in the elderly (â‰¥65 years) appeared similar to that seen in younger patients (&lt;65 years). Elderly patients receiving AGGRASTAT with heparin or heparin alone had a higher incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications than did younger patients, but the incremental risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with AGGRASTAT in combination with heparin compared to the risk in patients treated with heparin alone was similar regardless of age. No dose adjustment is recommended for the elderly population <span class="Italics">[see Dosage and Administration (2)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb11d5afc-69e9-427b-a406-8db11845db2d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>
							</h2>
<p class="First">Patients with moderate to severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have decreased plasma clearance of AGGRASTAT. Reduce the dosage of AGGRASTAT in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <span class="Italics">[see Dosage and Administration (2) and Clinical Pharmacology (12.3)]. </span></p>
<p>Safety and efficacy of AGGRASTAT has not been established in patients on hemodialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="L73c47d5f-f73d-4ce2-b2e9-9a386aba3f96"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE 
					</h1>
<p class="First">In clinical trials, inadvertent overdosage with AGGRASTAT occurred in doses up to 2 times the recommended dose for initial infusion doses. Inadvertent overdosage occurred in doses up to 9.8 times the 0.15 mcg/kg/min maintenance infusion rate.</p>
<p>The most frequently reported manifestation of overdosage was <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, primarily minor mucocutaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events and minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at the sites of cardiac catheterization <span class="Italics">[see WARNINGS AND PRECAUTIONS (5.1)]. </span></p>
<p>Overdosage of AGGRASTAT should be treated by assessment of the patientâ€™s clinical condition and cessation or adjustment of the drug infusion as appropriate. </p>
<p>AGGRASTAT can be removed by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="L0b74c60a-1618-44c9-8855-8b27334e7f98"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION 
					</h1>
<p class="First">AGGRASTAT contains tirofiban hydrochloride, a non-peptide antagonist of the platelet GP IIb/IIIa receptor, which inhibits platelet aggregation.  </p>
<p>Tirofiban hydrochloride monohydrate is chemically described as <span class="Italics">N</span>(butylsulfonyl)-<span class="Italics">O</span>-[4-(4-piperidinyl)butyl]-L-tyrosine monohydrochloride monohydrate.</p>
<p>Its molecular formula is C<span class="Sub">22</span>H<span class="Sub">36</span>N<span class="Sub">2</span>O<span class="Sub">5</span>Sâ€¢HClâ€¢H<span class="Sub">2</span>O and its structural formula is:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&amp;name=aggrastat-struct-formula.jpg"></p>
<p>Tirofiban hydrochloride monohydrate is a white to off-white, non-hygroscopic, free-flowing powder, with a molecular weight of 495.08. It is very slightly soluble in water. </p>
<p>AGGRASTAT Injection Premixed is supplied as a sterile solution in water for injection, for intravenous use only, in plastic containers of 100 mL or 250 mL.  Each 100 mL of the premixed, iso-osmotic intravenous injection contains 5.618 mg tirofiban hydrochloride monohydrate equivalent to 5 mg tirofiban (50 mcg/mL) and the following inactive ingredients: 0.9 g sodium chloride, 54 mg sodium citrate dihydrate, and 3.2 mg citric acid anhydrous. Each 250 mL of the premixed, iso-osmotic intravenous injection contains 14.045 mg tirofiban hydrochloride monohydrate equivalent to 12.5 mg tirofiban (50 mcg/mL) and the following inactive ingredients: 2.25 g sodium chloride, 135 mg sodium citrate dihydrate, and 8 mg citric acid anhydrous. </p>
<p>The pH of the solution ranges from 5.5 to 6.5 and may have been adjusted with hydrochloric acid and/or sodium hydroxide. The flexible container is manufactured from a specially designed multilayer plastic (PL 2408). Solutions in contact with the plastic container leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="L8f9aaa68-757e-4d85-822d-e23ad1d70886"></a><a name="section-11"></a><p></p>
<h1>12   CLINICAL PHARMACOLOGY
					</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="L6ccecbd1-8edb-407f-b1e9-229b11d5059a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
							</h2>
<p class="First">AGGRASTAT is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits <span class="Italics">ex vivo</span> platelet aggregation in a dose- and concentration-dependent manner.</p>
<p>When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min for 30 minutes followed by a 0.1 mcg/kg/min maintenance infusion, &gt;90% inhibition of platelet aggregation is attained by the end of the 30-minute infusion. When given according to the recommended regimen of 25 mcg/kg followed by a 0.15 mcg/kg/min maintenance infusion, &gt;90% inhibition of platelet aggregation is attained within 10 minutes. Platelet aggregation inhibition is reversible following cessation of the infusion of AGGRASTAT.  </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Lf6810eed-9ab0-4d36-b179-1883956c5f9e"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
							</h2>
<p class="First">AGGRASTAT inhibits platelet function, as demonstrated by its ability to inhibit <span class="Italics">ex vivo</span> adenosine phosphate (ADP)-induced platelet aggregation and prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in healthy subjects and patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. The time course of inhibition parallels the plasma concentration profile of the drug.</p>
<p>Following discontinuation of an infusion of AGGRASTAT 0.10 mcg/kg/min, <span class="Italics">ex vivo</span> platelet aggregation returns to near baseline in 4 to 8 hours in approximately 90% of patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. The addition of heparin to this regimen does not significantly alter the percentage of subjects with &gt;70% inhibition of platelet aggregation (IPA), but does increase the average <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, as well as the number of patients with <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> prolonged to &gt;30 minutes.  Similar platelet aggregation recovery rates are observed following discontinuation of a 0.15 mcg/kg/min infusion.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="L5648cf8d-9f2f-41de-b667-55f681b0b3d9"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
							</h2>
<p class="First">Tirofiban has a half-life of approximately 2 hours. It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban. Metabolism appears to be limited. </p>
<p>Tirofiban is not highly bound to plasma proteins and protein binding is concentration independent over the range of 0.01 to 25 mcg/mL. The unbound fraction in human plasma is 35%. The steady state volume of distribution of tirofiban ranges from 22 to 42 liters. </p>
<p>In healthy subjects, the plasma clearance of tirofiban ranges from 213 to 314 mL/min. Renal clearance accounts for 39 to 69% of plasma clearance. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="Lad82a0f7-169e-4dfb-b23f-aba0f949ee98"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<p class="First">There is no effect on clearance of tirofiban by sex, race, age, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>Plasma clearance of tirofiban is decreased about 40% in subjects with creatinine clearance &lt;60 mL/min and &gt;50% in patients with creatinine clearance &lt;30 mL/min, including patients requiring hemodialysis <span class="Italics">[see Dosage and Administration (2)]</span>. Tirofiban is removed by hemodialysis.</p>
<p></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Ld6df9863-9c84-4666-9711-616cc2c2626c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
					</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Lcf49c369-48c1-4a46-8804-64f5dc00a64f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 	</h2>
<p class="First">The carcinogenic potential of AGGRASTAT has not been evaluated.</p>
<p>Tirofiban HCl was negative in the <span class="Italics">in vitro </span>microbial mutagenesis and V-79 mammalian cell mutagenesis assays. In addition, there was no evidence of direct genotoxicity in the <span class="Italics">in vitro </span>alkaline elution and <span class="Italics">in vitro </span>chromosomal aberration assays. There was no induction of chromosomal aberrations in bone marrow cells of male mice after the administration of intravenous doses up to 5 mg tirofiban/kg (about 3 times the maximum recommended daily human dose when compared on a body surface area basis).</p>
<p>Fertility and reproductive performance were not affected in studies with male and female rats given intravenous doses of tirofiban up to 5 mg/kg/day (about 5 times the maximum recommended daily human dose when compared on a body surface area basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="L01064604-4930-4079-9b6f-899ad2c61360"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
					</h1>
<p class="First">Two large-scale clinical studies established the efficacy of AGGRASTAT in the treatment of patients with NSTE-ACS (<span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>/non-ST elevation MI). The two studies examined AGGRASTAT alone and added to heparin, prior to and after percutaneous coronary revascularization (if indicated) (PRISM-PLUS) and in comparison to heparin in a similar population (PRISM).  These trials are discussed in detail below. </p>
<p><span class="Italics">PRISM-PLUS (Platelet Receptor Inhibition for Ischemic Syndrome Management â€” Patients Limited by Unstable Signs and Symptoms) </span></p>
<p>In the double-blind PRISM-PLUS trial, 1570 patients with documented NSTE-ACS within 12 hours of entry into the study were randomized to AGGRASTAT (30 minute initial infusion of 0.4 mcg/kg/min followed by a maintenance infusion of 0.10 mcg/kg /min) in combination with heparin (bolus of 5,000 U followed by an infusion of 1,000 U/h titrated to maintain an APTT of approximately 2 times control) or to heparin alone.  All patients received concomitant aspirin unless contraindicated.  Patients who were medically managed or who underwent revascularization procedures were studied.  Patients underwent 48 hours of medical stabilization on study drug therapy, and they were to undergo angiography before 96 hours (and, if indicated, angioplasty/atherectomy, while continuing on AGGRASTAT and heparin for 12-24 hours after the procedure). AGGRASTAT and heparin could be continued for up to 108 hours.  </p>
<p>Exclusions included contraindications to anticoagulation, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span>, platelet count &lt;150,000/mm<span class="Sup">3</span>, and serum creatinine &gt;2.5 mg/dL. The mean age of the population was 63 years; 32% of patients were female and approximately half of the population presented with non-ST elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. On average, patients received AGGRASTAT for 71 hours. </p>
<p>A third group of patients was initially randomized to AGGRASTAT alone (no heparin). This arm was stopped when the group was found, at an interim look, to have greater mortality than the other two groups. </p>
<p>The primary endpoint of the study was a composite of refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, new MI and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within 7 days. There was a 32% risk reduction in the overall composite primary endpoint.  The components of the composite were examined separately and the results are shown in Table 5. Note that the sum of the individual components may be greater than the composite (if a patient experiences multiple component events only one event counts towards the composite).  </p>
<a name="col8"></a><table frame="box" width="70%">
<caption><span>Table 5 Primary outcomes at 7 days in PRISM-PLUS</span></caption>
<col align="left" width="40%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><p class="First">Endpoint</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">AGGRASTAT+</p>
<p>Heparin</p>
<p>(n=773)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Heparin</p>
<p>(n=797)</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Risk Reduction</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">p-value</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, new MI, and refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> at 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.004</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">---</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">---</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â MI</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.0%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">47%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.006</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><p class="First">Â Â Â Refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12.7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.023</p></td>
</tr>
</tbody>
</table>
<p>The benefit seen at 7 days was maintained over time. The risk reduction in the composite endpoint at 30 days and 6 months is shown in the Kaplan-Meier curve below. </p>
<p><img alt="figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&amp;name=aggrastat-figure1.jpg"></p>
<p><span class="Bold">Figure 1. Time to first event of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, new MI, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> in PRISM-PLUS
</span></p>
<p>An analysis of the results by sex suggests that women who are medically managed or who undergo subsequent PTCA/atherectomy may receive less benefit from AGGRASTAT (95% confidence limits for relative risk of 0.61-1.74) than do men (0.43-0.89) (p=0.11).  This difference may be a true treatment difference, the effect of other differences in these subgroups, or a chance occurrence.  </p>
<p>Approximately 90% of patients in the PRISM-PLUS study underwent coronary angiography and 30% underwent angioplasty/atherectomy during the first 30 days of the study. The majority of these patients continued on study drug throughout these procedures. AGGRASTAT was continued for 12-24 hours (average 15 hours) after angioplasty/atherectomy. The effects of AGGRASTAT at Day 30 did not appear to differ among sub-populations that did or did not receive PTCA or CABG, both prior to and after the procedure.</p>
<p><span class="Italics">PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management)</span></p>
<p>In the PRISM study, a randomized, parallel, double-blind study, 3232 patients with NSTE-ACS intended to be managed without coronary intervention were randomized to AGGRASTAT (initial dose of 0.6 mcg/kg/min for 30 minutes followed by 0.15 mcg/kg/min for 47.5 hours) or heparin (5000-unit intravenous bolus followed by an infusion of 1000 U/h for 48 hours). The mean age of the population was 62 years; 32% of the population was female and 25% had non-ST elevation MI on presentation. Thirty percent had no ECG evidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>. Exclusion criteria were similar to PRISM-PLUS. The primary endpoint was the composite endpoint of refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, MI or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at the end of the 48-hour drug infusion. The results are shown in Table 6. </p>
<a name="col9"></a><table frame="box" width="70%">
<caption><span>Table 6 Primary outcomes in PRISM â€“ <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Cardiac Ischemia</span> Events</span></caption>
<col align="left" width="40%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><p class="First">Composite Endpoint (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">AGGRASTAT</p>
<p class="Default">(n=1616)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Heparin</p>
<p class="Default">(n=1616)</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Risk Reduction</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">p-value</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><p class="First">2 Days (end of drug infusion)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.8%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.6%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.015</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><p class="First">7 Days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11.3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.33</p></td>
</tr>
</tbody>
</table>
<p>In the PRISM study, no adverse effect of AGGRASTAT on mortality at either 7 or 30 days was detected. This result is different from that in the PRISM-PLUS study, where the arm that included AGGRASTAT without heparin (n=345) was dropped at an interim analysis by the Data Safety Monitoring Committee for increased mortality at 7 days. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="L546999ed-05cf-40f9-9297-843f55d84e34"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
					</h1>
<p class="First">AGGRASTAT Injection Premixed 5 mg tirofiban per 100 mL (50 mcg per mL) and 12.5 mg tirofiban per 250 mL (50 mcg per mL) are clear, non-preserved, sterile solutions premixed in a vehicle made iso-osmotic with sodium chloride, and are supplied as follows: </p>
<ul>
<li>
<span class="Bold">NDC</span> 25208-002-01, 100 mL single-dose INTRAVIA containers (PL 2408 Plastic).</li>
<li>
<span class="Bold">NDC</span> 25208-002-02, 250 mL single-dose INTRAVIA containers (PL 2408 Plastic). </li>
</ul>
<p>FOR INTRAVENOUS USE ONLY</p>
<p>Store AGGRASTAT at 25Â°C (77Â°F) with excursions permitted between 15-30Â°C (59-86Â°F)  (see USP Controlled Room Temperature). Do not freeze. Protect from light during storage. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="L97aa33ad-cbfc-480f-8563-4dd140517c66"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients to watch closely for any signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and to report these to their health care provider when they occur.</p>
<p>Advise patients to discuss with their health care provider their use of any other medications, including over-the-counter or herbal products prior to AGGRASTAT use.</p>
<p>Patent: www.medicure.com/aggrastat/patents</p>
<p>AGGRASTAT is manufactured for:</p>
<p>MEDICURE INTERNATIONAL, INC.</p>
<p>by:</p>
<p>BAXTER HEALTHCARE CORPORATION</p>
<p>Deerfield, Illinois 60015 USA</p>
<p>Distributed by:</p>
<p>MEDICURE PHARMA, INC.<br>
Somerset, NJ 08873  USA<br>
1-800-509-0544<br>
Printed in USA<br>
07-19-74-803<br>


* Registered trademark of Medicure International, Inc.<br>
Â© 2015 <br>
Copyright used under license.<br> 
All rights reserved.<br>

Intravia is a registered trademark of Baxter International Inc.
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First">Insert</p>
<p><img alt="Insert" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&amp;name=pack-1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First">Container</p>
<p><img alt="Container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&amp;name=pack-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First">Carton</p>
<p><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&amp;name=pack-3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AGGRASTATÂ 		
					</strong><br><span class="contentTableReg">tirofiban injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25208-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TIROFIBAN HYDROCHLORIDE</strong> (TIROFIBAN) </td>
<td class="formItem">TIROFIBAN</td>
<td class="formItem">5Â mg Â inÂ 100Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">3.2Â mg Â inÂ 100Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">54Â mg Â inÂ 100Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">900Â mg Â inÂ 100Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25208-002-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:25208-002-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">250 mL in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020913</td>
<td class="formItem">05/14/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Medicure International Inc
							(860240324)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Medicure International Inc (860240324)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">manufacture(25208-002), analysis(25208-002), pack(25208-002), label(25208-002)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0ca681e5-b8a1-43f0-a96d-bbb5a9f23f8c</div>
<div>Set id: fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f</div>
<div>Version: 8</div>
<div>Effective Time: 20150430</div>
</div>
</div>Â <div class="DistributorName">Medicure International Inc</div></p>
</body></html>
